TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06621836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICPB H
Description: ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group H will receive 10 ml 0.25 % bupivacaine he technique will be repeated on the opposite side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICPB - L
Description: ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group L will receive 10 ml 0.125% bupivacaine. The technique will be repeated on the opposite side
Study: NCT04964934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Dosage formulation: palbociclib tablets/capsules will be administered orally
Study: NCT05607680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously (SC) once a week.
Study: NCT04964934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Dosage formulation: abemaciclib tablets will be administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Dosage formulation: abemaciclib tablets will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonist
Description: Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonist
Description: Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Dosage formulation: ribociclib tablets will be administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib
Description: Dosage formulation: ribociclib tablets will be administered orally
Study: NCT05607680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.
Study: NCT06681935

Intervention type: PROCEDURE
Intervention: Oral Cavity Reconstruction
Description: This procedure includes a planned surgical connection from the oral cavity to the neck soft tissues which is repaired through free or pedicled flap reconstruction.
Study: NCT06572813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: Bortezomib Injection, a kind of chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: Bortezomib Injection, a kind of chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium
Study: NCT06622616

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EVALUATE THE EFFECT OF ACHETA DOMESTICUS POWDER CONSUMPTION ON GLUCOSE HOMEOSTASIS AND INTESTINAL DYSBIOSIS
Description: The study will have two arms, the functional group with A. domesticus powder (n=60) and a placebo group that will take a vegetable protein powder with a similar macronutrient composition (n=60). This population will be classified according to sex and BMI, and their nutritional-metabolic status (insulin resistance or not).~The study will include analysis of phenotypic data collection (medical history, lifestyle, diet, etc.); biochemical data: glucose, lipid, iron profile, blood count, and analysis of inflammation markers; genotyping, epigenetic analysis (methylation and mi-RNAs), targeted metabolomics (glycome and tryptophan) and metagenomic analysis of stool (16s rRNA sequencing for taxonomic identification study). Using continuous monitoring devices (glucose monitoring using a sensor and physical activity using an activity bracelet), lifestyle parameters (physical activity, circadian rhythms, sleep, stress, etc.) and blood glucose will be evaluated.
Study: NCT06572813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium
Study: NCT06532032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as IV infusion.
Study: NCT06126900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone medication intake reminder + educational and motivational text messaging
Description: The intervention includes the use of a smartphone-based medication intake reminder, along with two educational and motivational text messages during the therapy period.
Study: NCT06539351

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: 4mm skin punch biopsy
Study: NCT06622616

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EVALUATE THE EFFECT OF ACHETA DOMESTICUS POWDER CONSUMPTION ON GLUCOSE HOMEOSTASIS AND INTESTINAL DYSBIOSIS
Description: The study will have two arms, the functional group with A. domesticus powder (n=60) and a placebo group that will take a vegetable protein powder with a similar macronutrient composition (n=60). This population will be classified according to sex and BMI, and their nutritional-metabolic status (insulin resistance or not).~The study will include analysis of phenotypic data collection (medical history, lifestyle, diet, etc.); biochemical data: glucose, lipid, iron profile, blood count, and analysis of inflammation markers; genotyping, epigenetic analysis (methylation and mi-RNAs), targeted metabolomics (glycome and tryptophan) and metagenomic analysis of stool (16s rRNA sequencing for taxonomic identification study). Using continuous monitoring devices (glucose monitoring using a sensor and physical activity using an activity bracelet), lifestyle parameters (physical activity, circadian rhythms, sleep, stress, etc.) and blood glucose will be evaluated.
Study: NCT06683690

Intervention type: PROCEDURE
Intervention: Measurement of TGF- β1 in leprosy patients
Description: Study TGF- β1gene polymorphism in leprosy patients, and Correlate their results with different types of leprosy before and after treatment.

Intervention type: PROCEDURE
Intervention: Measurement of TGF- β1 in leprosy patients
Description: Study TGF- β1gene polymorphism in leprosy patients, and Correlate their results with different types of leprosy before and after treatment.
Study: NCT05912517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as an intravenous infusion.
Study: NCT05908734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as IV infusion.
Study: NCT06632184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron (ODT) + Bicarbnate solution
Description: This intervention involves the administration of an intraperitoneal solution of ondansetron combined with bicarbonate during laparoscopic cholecystectomy. The addition of bicarbonate is intended to enhance the analgesic properties of ondansetron by increasing its pH, which may improve its efficacy in controlling postoperative pain. This formulation is being compared to ondansetron in saline to determine its superiority in reducing pain, as well as the need for rescue analgesia and postoperative nausea and vomiting (PONV). The intervention is administered once intraoperatively.
Study: NCT05908734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as IV infusion.
Study: NCT05455684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant
Description: Aticaprant will be administered orally as tablets.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally as tablets.
Study: NCT04936308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.
Study: NCT06632184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron (ODT) + Saline Solution
Description: This intervention involves the administration of ondansetron in saline solution, serving as the control arm in the study. Like the bicarbonate formulation, this solution is administered intraperitoneally during laparoscopic cholecystectomy. Ondansetron is a standard antiemetic used to prevent nausea and vomiting. This formulation will serve to evaluate whether adding bicarbonate enhances pain control compared to the saline solution.
Study: NCT06047509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Laser Ablation
Description: Removal of cancerous tissue through the direct application of laser energy
Study: NCT06010030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Transcranial Direct Current Stimulation
Description: High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. Anodal or sham tDCS will be administered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: Participants will receive either semantic or phonological focused speech therapy
Study: NCT04855253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777
Description: E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777
Description: E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777
Description: E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777
Description: E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
Study: NCT05518149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant
Description: Aticaprant 10 mg tablet will be administered orally.
Study: NCT06525571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysview
Description: Blue light cystoscopy uses hexyl aminolevulinate (HAL, branded in the United States as Cysview), a prodrug which accumulates in the bladder tumors and improves the tumor's visualization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Description: Cystoscopy procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Description: Cystoscopy procedure
Study: NCT05327114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.
Study: NCT04883619

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab dose 1 and dose 2 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab dose 1 and dose 2 will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-care treatment
Description: Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care treatment
Description: Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care treatment
Description: Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
Study: NCT05663645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health insurance educational guide
Description: The educational guide includes 4 content areas: 1) Definition of key insurance terms; 2) premiums, deductibles across the five 2023 health plans; 3) Summary of how premiums and deductibles can affect out of pocket costs; 4) Guide to finding in-network IVF providers and facilities.
Study: NCT05244044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation in primary care
Description: Pulmonary rehabilitation consists breathing exercises, exercise capacity, muscle strength and change towards an active lifestyle.
Study: NCT04879940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merit Medical Embospheres
Description: Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will undergo standard of care definitive radiation therapy.
Study: NCT04918225

Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging
Description: Encephalic (about 30 minutes\*)~* lesion location assessment: 3D FLAIR, 3DT1, 3DT2 (standard OFSEP protocol)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1)~* tract location assessment: 30 directions diffusion imaging (standard OFSEP protocol)~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities~  ● Spinal cord (about 50 minutes\*)~* lesion location assessment: cervical and thoracic sagittal T2 TSE (0.7x0.7x2.5mm3), axial cervical MEDIC T2\* (0.7x0.7x3mm3), axial thoracic T2 (0.5x0.5x3mm3)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1, 0.7x0.7x3mm3) on the cervical cord and on the thoracic cord~* tract location assessment: performed from registration on atlas~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities
Study: NCT05630040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation
Description: Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-invasive vagus nerve stimulation
Description: Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Participants will take a placebo device home for 6 weeks and use daily.
Study: NCT06453928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop Insulin Pump System
Description: Patients will be started on an automated insulin delivery system.
Study: NCT04918225

Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging
Description: Encephalic (about 30 minutes\*)~* lesion location assessment: 3D FLAIR, 3DT1, 3DT2 (standard OFSEP protocol)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1)~* tract location assessment: 30 directions diffusion imaging (standard OFSEP protocol)~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities~  ● Spinal cord (about 50 minutes\*)~* lesion location assessment: cervical and thoracic sagittal T2 TSE (0.7x0.7x2.5mm3), axial cervical MEDIC T2\* (0.7x0.7x3mm3), axial thoracic T2 (0.5x0.5x3mm3)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1, 0.7x0.7x3mm3) on the cervical cord and on the thoracic cord~* tract location assessment: performed from registration on atlas~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological examination
Description: Global disability will be scored using the Expanded Disability Status Scale score

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple Sclerosis Functional Composite
Description: * Walking disability will be scored using the 25-foot timed-walked test~* Arm disability will be scored using the nine-hole peg test

Intervention type: DIAGNOSTIC_TEST
Intervention: Physiotherapist examination
Description: * American Society Injury. Association motor subscore for each limb~* The muscle strength using a dynamometer. Two muscle groups will be tested for the upper (elbow flexors and extensors) and lower limbs (hip flexors and ankle dorsiflexion).~* The Ashworth Scale and the Tardieu Scale to assess spasticity.~* 6 minutes walking test~* Fatigue Severity Scale~* MFIS : Modified Fatigue Impact Scale
Study: NCT06559527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111
Description: Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111
Description: Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111
Description: Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111
Description: Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111
Description: Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.
Study: NCT04417803

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: plasmatic sampling

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: plasmatic sampling

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: plasmatic sampling
Study: NCT06078267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPumlonary Management System (CPM)
Description: The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
Study: NCT05946317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual nerve function assessed after removal of mandibular third molar with lingual split technique
Description: The lingual split technique is based on using chisel and hammer in bone removing. After the buccal and lingual flaps are raised and retracted. Two buccal bone cutting with horizontal cutting up between them are performed, The disto-lingual bone fragment is fractured inward by placing the cutting edge of the chisel at 45 degrees with the surface of the bone and directed towards the lower second premolar of the opposite side. By maintaining the cutting edge of the chisel parallel to the external oblique ridge, a few light taps with the mallet will separate the lingual plate from the rest of the alveolar bone. And it released from soft tissues, buccally force is applied to roll the whole tooth lingually. The neurological function of the lingual nerve was assessed after the demise of local anesthesia, then the location of the disorder and taste function and healing time are determined by sensory neurological tests on a graphic map that divides the tongue into sextants.